Next-Generation
Protein Conjugation

At CatenaBio, we envision a future where therapeutics are limited only by imagination.

Breakthrough Protein Conjugation

CatenaBio’s CysTyr platform utilizes the novel Catenase enzyme, which catalyzes the formation of our proprietary C-Y Bond using only native amino acids.

Our approach eliminates the current size and complexity constraints that restrict molecule connections. This allows attachment of multiple different cargoes to a protein, delivering new therapeutic modalities.

All this is accomplished with greater speed, stability, selectivity, and scalability than current approaches.

Explore the science
A molecule with an inactivated n- or c-terminal tyrosine.

Our approach eliminates the current size and complexity constraints that restrict molecule connections. This allows attachment of multiple different cargoes to a protein, delivering new therapeutic modalities.

All this is accomplished with greater speed, stability, selectivity, and scalability than current approaches.

Explore the science
A molecule with an inactivated n- or c-terminal tyrosine.
A molecule conjugated with a second molecule using the C-Y bond

Exceptional Minds
Exceptional Innovation

Our team has been instrumental in advancing medical research. Our technology was developed in the same halls where CRISPR was born, a connection that fuels our passion for pushing the boundaries of scientific discovery.

Meet our team

CatenaBio Presents Poster on Multi-Payload Conjugates at the American Association for Cancer Research (AACR) Annual Meeting

April 8, 2024  |  San Diego, CA

CatenaBio Selected to Present on its Next Generation Platform and Multi Payload Conjugates (MPC®) at the Berkeley Bio Startup Showcase @JPM

January 4, 2024  |  Berkeley, CA